Biogen Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Biogen şirketinin toplam hissedar öz sermayesi $15.9B ve toplam borcu $6.3B olup, bu da borç-öz sermaye oranını 39.6% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $26.8B ve $10.9B dir. Biogen 'in FAVÖK'ü $2.2B faiz karşılama oranı 19.9 dur. Şirketin $1.9B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

39.6%

Borç/özkaynak oranı

US$6.29b

Borç

Faiz karşılama oranı	19.9x
Nakit	US$1.91b
Eşitlik	US$15.89b
Toplam yükümlülükler	US$10.92b
Toplam varlıklar	US$26.80b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: BIIB 'nin kısa vadeli varlıkları ( $7.1B ) kısa vadeli yükümlülüklerini ( $3.1B ) aşıyor.

Uzun Vadeli Yükümlülükler: BIIB 'un kısa vadeli varlıkları ( $7.1B ) uzun vadeli yükümlülüklerini ( $7.8B ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: BIIB 'nin net borç/öz sermaye oranı ( 27.6% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: BIIB 'nin borç/öz sermaye oranı son 5 yılda 45.9% seviyesinden 39.6% seviyesine düştü.

Borç Kapsamı: BIIB 'nin borcu işletme nakit akışı ( 28.4% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: BIIB 'in borcuna ilişkin faiz ödemeleri EBIT ( 19.9 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Biogen Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Eisai Co., Ltd. and Biogen Inc. Completes Rolling Submission to US FDA for LEQEMBI Biologics License Application for Subcutaneous Maintenance Dosing

Biogen Inc. Appoints Daniel Quirk as Chief Medical Officer and Head of Medical Affairs

Biogen Inc. Appoints Daniel Quirk as Chief Medical Officer and Head of Medical Affairs

Biogen Inc. Announces Chief Financial Officer Changes

Biogen Inc. to Report Q3, 2024 Results on Oct 30, 2024

Biogen Inc. Announces Elects Lloyd B. Minor and Sir Menelas (Mene) Pangalos as Directors, Effective October 1, 2024 and January 1, 2025, Respectively

Second quarter 2024 earnings released: EPS: US$4.01 (vs US$4.09 in 2Q 2023)

Eisai Co., Ltd. and Biogen Inc. Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of Sage-324 (BIIB124) for the Treatment of Essential Tremor

Biogen Inc. (NasdaqGS:BIIB) completed the acquisition of Human Immunology Biosciences, Inc. from a group of sellers.

Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in China

Biogen Inc. to Report Q2, 2024 Results on Aug 01, 2024

Biogen Inc. (NasdaqGS:BIIB) agreed to acquire Human Immunology Biosciences, Inc. from Alpha Wave Global, LP, Jeito Capital S.A., Viking Global Investors LP and others for approximately $1.8 billion.

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Biogen Inc., Annual General Meeting, Jun 20, 2024

Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA

First quarter 2024 earnings released: EPS: US$2.71 (vs US$2.69 in 1Q 2023)

Biogen Inc. Provides Earnings Guidance for the Full Year of 2024

Biogen Inc. to Report Q1, 2024 Results on Apr 24, 2024

Full year 2023 earnings released: EPS: US$8.02 (vs US$20.97 in FY 2022)

Biogen Inc. Announces Plans to Reprioritize its Resources in Alzheimer’s Disease, Strategic Therapeutic Area Expected to Drive Near and Long-Term Growth

Biogen Inc. to Report Q4, 2023 Results on Feb 13, 2024

CHMP Issues Positive Opinion for Biogen Inc.'s SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia

Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE (Zuranolone) 50 mg (Two 25 mg Capsules Per Day) CIV

Biogen Inc. Updates Revenue Guidance for the Fiscal Year 2023

New minor risk - Earnings quality

Third quarter 2023 earnings released: US$0.47 loss per share (vs US$7.86 profit in 3Q 2022)

Biogen Inc. Appoints Monish Patolawala to Its Board of Directors, Effective from January 1, 2024

Eisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's Disease

Biogen Inc. to Report Q3, 2023 Results on Nov 08, 2023

FDA Approves Biogen Inc.'s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

Biogen Inc. (NasdaqGS:BIIB) acquired Reata Pharmaceuticals, Inc. (NasdaqGM:RETA).

Eisai Co., Ltd. and Biogen Inc. Announces LEQEMBI Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’S Disease in Japan

Dr Reddy's Laboratories Reportedly Jumps into the Fray for Biogen's Biosimilars

Biogen Inc. Announces the Appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research Effective 2 October 2023

Sanofi Reportedly Second Bidder for Reata

Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Reata Pharmaceuticals, Inc. (NasdaqGM:RETA) from shareholders for approximately $7 billion.

Biogen Inc. Reaffirms Earnings Guidance for the Full Year of 2023

Second quarter 2023 earnings released: EPS: US$4.09 (vs US$7.25 in 2Q 2022)

Eisai Co., Ltd. and Biogen Inc. Present Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023

Biogen Inc. to Report Q2, 2023 Results on Jul 25, 2023

Biogen Inc. to Report Q2, 2023 Results on Jul 25, 2023

Eisai Co., Ltd. and Biogen Inc. Announces FDA Grants Traditional Approval for LEQEMBI® (Lecanemab-Irmb) for the Treatment of Alzheimer’s Disease

Biogen Announces Board Changes

Biogen Inc., Annual General Meeting, Jun 26, 2023

Biogen Inc., Annual General Meeting, Jun 26, 2023

Biogen Inc., Annual General Meeting, Jun 26, 2023

Eisai Co., Ltd. and Biogen Inc. Announces the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee

Eisai Co., Ltd. and Biogen Inc. Announce Health Canada Accepts New Drug Submission for Lecanemab

Insider recently sold CHF716k worth of stock

First quarter 2023 earnings released: EPS: US$2.69 (vs US$2.07 in 1Q 2022)

Biogen Inc. Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: EPS: US$20.97 (vs US$10.44 in FY 2021)

Biogen Inc. and Sage Therapeutics, Inc. Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Eisai Co., Ltd. and Biogen Inc. Announce Lecanemab Receives Priority Review Status in Japan

Eisai Co., Ltd. and Biogen Inc. Announce European Medicines Agency Accepts Marketing Authorization Application for Lecanemab

Biogen Inc. to Report Q4, 2022 Results on Feb 15, 2023

Eisai Co., Ltd. and Biogen Inc. Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe

Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin